HerbertLancashireDupontMD

Clinical Trials

• Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea Start of enrollment: 2004 Jun 01

  Completed

  Phase 4

• Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Start of enrollment: 2004 Jan 01

  Completed

  Phase 3

• Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease Start of enrollment: 2006 Jul 20

  Completed

  Phase 2

• Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea Start of enrollment: 2006 Aug 01

  Completed

  Phase 3

• Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis Start of enrollment: 2004 Jan 01

  Completed

  Phase 2

• ETEC Logistics Trial (TREK) Start of enrollment: 2006 May 01

  Completed

  Phase 2

• Study to Determine the Best Way to Measure How Quickly the Drug Can Give Relief From Sudden Diarrhea Start of enrollment: 2008 Oct 01

  Completed

  Phase 4

• Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study Start of enrollment: 2009 Oct 01

  Completed

  Phase 3

• SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01

  Completed

  Phase 2

• Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients Start of enrollment: 2017 Jul 15

  Withdrawn

  Phase 1, Phase 2

• Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI) Start of enrollment: 2017 Dec 21

  Terminated

  Phase 2

• Study of the Fecal Microbiome in Patients With Parkinson's Disease Start of enrollment: 2019 May 15

  Completed

  Phase 1

• Fecal Microbiota Transplantation (FMT): PRIM-DJ2727

  Available

• A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease Start of enrollment: 2023 Dec 01

  Withdrawn

  Phase 2

  Roles: Principal Investigator, Contact

• Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis Start of enrollment: 2020 Sep 14

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis Start of enrollment: 2023 Dec 15

  Recruiting

  Phase 1

  Roles: Principal Investigator, Contact

• Join now to see all